IVS-Final statement - International Workshop on PET in Lymphoma
The five-point visual assessment is applied as proposed at the Deauville consensus meeting. ⢠A cohort of ABVD-treated advanced-stage HL patients has been ...
Validation study First International Workshop on Interim PET/CT in Lymphoma
Purpose • To validate the results of previously published studies in HL and DLBCL • To investigate the consensus criteria on an international cohort of lymphoma patients currently being collected • To assess the interobserver variability using the consensus criteria
Methods • Cases are collected retrospectively • Patients eligible if interim PET/CT performed after 2 cycles of chemotherapy • Patients excluded if clinical decisions are based on interim PET/CT results alone • A baseline PET/CT is mandatory • Only PET/CT technology allowed
Hodgkin Lymphoma • The five-point visual assessment is applied as proposed at the Deauville consensus meeting • A cohort of ABVD-treated advanced-stage HL patients has been collected to validate previous results • This cohort will soon be expanded for assessment of consensus criteria, including all clinical stages of disease • Assessment of the additional value of SUV analysis
Diffuse Large B-cell Lymphoma • The five-point visual assessment is applied as proposed at the Deauville consensus meeting • Assessment of the additional value of SUV analysis as proposed in the recent publication by the GELA group (Itti et al.) • Stratified analysis according to therapy (14- vs 21-day schedules and +/rituximab) and prognostic score (IPI)
Next steps • May 2009: End of accrual of cases • September 2009: All images and clinical data collected • February 2010: End of analysis • April 2010, Menton: First report of results PET/CT review panel: Barrington S, Biggi A, Hutchings M, Meignan M + any interested colleagues from centres with significant contribution of cases
See you in Menton (France)
Second International Workshop on Interim-PET in lymphoma Menton, April, 9-10, 2010
published in Leukemia Lymphoma. ⢠Would the next step be :Imaging in ... lymphoma subtypes (FL,MCL,T-lymphoma ). 3. Identify key area of research in ...
FDG-PET after 2 cycles appears highly predictive, particularly for ... features (bulk, 3+ sites). ⢠All prognostic ... Assumptions: â 75% PET-negative after 2 ABVD.
Apr 9, 2010 - Haematology Torino and Rome. Second International workshop ... >No concomitant cardiac, liver, lung or renal disease. >HIV negativity, HCV ...
Staging and risk assessment of marginal zone lymphoma: ââ¦The value of positron emission ... MALT originating from the left lacrimal gland. PET-CT in MALT ...
if + (scores 4-5) or equivocal (score 3) then PET after 2 ABVD cycle. ⢠N=199 HL. 54 I-IIA .... Baseline MTV predictive of PFS and OS although tumor bulk was not.
Apr 8, 2010 - Positivity/Reference background. â¢Nearby background. â¢Mediastinal blood pool ... On which curve is this patient? Significance of minimal ...
Therapy ABVD or EBVD x 6 ± consolidation or IF radiotherapy. Visual assessment: ... LYMPHOMA. 44 HIV-related HL patients enrolled in 9 European centers.
3rd International Workshop on Interim PET in Lymphoma. Menton, September 27, 2011. Poster Discussion. Poster discussion. NHL. Ulrich Dührsen. Department ...
Various Rent-A-Car Companies can be found in the airport such as: Ada, Avis, Budget, Europcar, Hertz,. National Citer and Sixt. ⢠13 connections by regular bus ...
A 110 - Mounier N, Bower M, Spina M, Besson C, Schiantarelli C, Re A Bonnet F ..... Medicine Unit, Ospedale Policlinico, Padova; (7) Nuclear Medicine Unit, Ospedale La ...... Results: The average (median) time per scan upload and download.
Apr 8, 2010 - PET-positive after two courses of. ABVD and comparison of RT on prior bulk versus no RT in PET-negative patients at the end of chemotherapy.
Second international workshop on interim-PET in lymphoma. Menton (France), Palais de l'Europe, April 8-9th, 2010. Under the auspices of GELA, IIL, EORTC, ...
Sep 25, 2011 - lymphoma, new radiotracers and new imaging modalities. ⢠Evolving drugs: the era of targeted therapy could change the way we use PET ...
However, need for additional markers to identify curable from refractory/fatal patients? Cured. Fatal. Need to improve IPI. ⢠Biomarkers with prognostic relevance.
